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Abstract
Background Phase 3 clinical studies have shown that
long-term treatment with tenofovir disoproxil fumarate
(TDF) can suppress hepatitis B viral load and promote
significant fibrosis regression and cirrhosis reversal in a
majority of treated chronic hepatitis B (CHB) patients. This
retrospective analysis investigated the impact of baseline
cirrhosis status on virologic, serologic, and histologic
outcomes in patients treated with TDF.
Methods Patients enrolled in studies GS-US-174-0102
and GS-US-174-0103 who had baseline liver biopsy–di-
agnosed cirrhosis and entered the open-label phase of the
studies were included in the virologic and serologic ana-
lyses. Patients (both HBeAg positive and negative) with
paired liver biopsies at baseline and 5 years (N = 348)
were included in a histologic analysis.
Results After 5 years on study, comparing patients with
and without baseline cirrhosis, respectively: 99.2 and
98.0 % achieved virologic response (hepatitis B viral
load \ 69 IU/ml) (p = 0.686); 79.7 and 81.9 % had nor-
mal serum levels of alanine aminotransferase (p = 0.586);
4.0 and 1.2 % developed hepatocellular carcinoma
(p = 0.044). In HBeAg-positive patients with and without
baseline cirrhosis, HBsAg loss occurred in 14.4 and 8.3 %
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of patients, respectively (p = 0.188). One HBeAg-negative
patient had HBsAg loss.
Conclusions This represents the largest analyses to date
of CHB patients with sequential liver biopsies demon-
strating that treatment with TDF for up to 5 years is as-
sociated with favorable virologic, serologic, and histologic
outcomes, regardless of baseline cirrhosis status. Notably,
histologic improvement was observed in the majority of
cirrhotic and noncirrhotic patients.
Keywords Antiviral agent  Chronic hepatitis B 
Cirrhosis  Hepatitis B e antigen  Hepatitis B surface
antigen  Tenofovir disoproxil
Background
It is estimated that up to 40 % of patients with chronic
hepatitis B (CHB) will progress to cirrhosis, liver failure,
or hepatocellular carcinoma (HCC) [1]. In fact, hepatitis B
infection may account for 30 % of cirrhosis cases and
50 % of HCC cases worldwide [2]. Because high serum
hepatitis B virus (HBV) DNA levels are associated with
increased risk of developing cirrhosis and HCC [3, 4], in-
tervening with highly potent antiviral agents may alter the
clinical course and prevent the development of these ad-
verse liver-related outcomes [2, 5]. There are limited data
regarding the impact of long-term antiviral therapy on
clinical outcomes in cirrhotic CHB patients. However, over
the past decade, studies of oral nucleot(s)ide analogs have
suggested that reducing HBV viral load may prevent dis-
ease progression in CHB patients and, in a small patient
series, reverse preexisting cirrhosis [6–9].
Published results from a combined cohort of two on-
going phase 3 studies of tenofovir disoproxil fumarate
(TDF) in CHB patients (N = 641) have provided evidence
that long-term HBV suppression can promote significant
fibrosis regression and cirrhosis reversal in the majority of
treated patients [10]. Of the 348 patients with paired liver
biopsies at baseline and year 5, 87 % experienced histo-
logic improvement (defined as a C 2-point reduction in the
Knodell necroinflammatory score without worsening of
fibrosis) and 51 % experienced fibrosis regression [10].
Furthermore, 74 % of the 96 patients with baseline cir-
rhosis exhibited reversal of cirrhosis at year 5 [10]. Of
these patients, all but one had Ishak fibrosis scores im-
proved by C2 units, and 58 % had fibrosis scores improved
by C3 units. Twenty-four (25 %) patients had no change in
liver fibrosis. One (1 %) patient had worsening of fibrosis
from baseline to year 5 (Ishak fibrosis score increase from
5 to 6). The question remains, however, whether long-term
outcomes in CHB patients treated with TDF are influenced
by patients’ baseline cirrhosis status. In this subanalysis of
the two phase 3 studies, we report long-term clinical, vi-
rologic, serologic, and histologic outcomes in patients with
and without baseline cirrhosis.
Methods
Study design
This retrospective pooled analysis investigates clinical,
serologic, and histologic outcomes in a subset of CHB pa-
tients who had liver biopsy at baseline and year 5. These
patients were initially treated for 1 year (48 weeks) with
either adefovir dipivoxil (ADV) or TDF in two randomized,
controlled phase 3 studies [GS-US-174-0102 (study 102) and
GS-US-174-0103 (Study 103)] before continuing to open-
label TDF for a planned additional 9 years. The studies are
registered with ClinicalTrials.gov (NCT00117676 and
NCT00116805, respectively). Six hundred forty-one pa-
tients were initially randomized; of these, 634 had liver
biopsy data available at baseline. Complete medical history
and full physical examination were done at baseline. Key
exclusion criteria were coinfection with HIV-1, or hepatitis
C or D virus, evidence of HCC, a creatinine clearance
\70 ml/min, a hemoglobin level\8 g/dl, a neutrophil count
\1,000/mm3, and liver decompensation or failure. Decom-
pensated liver disease was defined as conjugated bilirubin
[1.5 9 the upper limit of normal (ULN), prothrombin time
[1.5 9 ULN, platelet count\75,000/mm3, serum albumin
\3.0 g/dl, or prior history of hepatic decompensation (e.g.,
ascites, jaundice, encephalopathy, variceal hemorrhage).
Detailed descriptions of the study populations, design, and
methods have been reported previously [10–12] (Fig. 1a).
Demographic, baseline, and on-treatment characteristics
of patients who had cirrhosis (Ishak fibrosis score C5) at
baseline were compared with patients who did not have
cirrhosis (Ishak fibrosis score B4) at baseline [13].
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Measures of biochemical response included the proportion
of patients with normal serum levels of alanine amino-
transferase (ALT) and the proportion of patients with ab-
normal ALT levels at baseline who achieved ALT
normalization (at or below the upper limit of normal
(ULN), which was 34 IU/ml for females and 43 IU/ml for
males). Serologic end points included serum hepatitis B
surface antigen (HBsAg) loss and serum hepatitis B e
antigen (HBeAg) loss. Virologic response was defined as
the proportion of patients with plasma HBV DNA\69 IU/
ml. The proportion of patients with plasma HBV DNA
\29 IU/ml, the lower limit of quantification of the COBAS
TaqMan assay, was also analyzed [10].
Patients who had paired liver biopsies at baseline and at
year 5 were evaluated for histologic changes. The changes
from baseline in Knodell necroinflammatory and Ishak
fibrosis scores were compared between patients with and
without cirrhosis. The procedure for evaluating liver
biopsies has been previously described [10]. Regression of
fibrosis was defined as a C1-point decline in the Ishak
fibrosis score [10, 13].
Statistical analyses
Descriptive statistics (mean and standard deviation for
continuous variables, frequency and percentage for cate-
gorical variables) was used to summarize baseline demo-
graphics and disease characteristics for patients with and
without baseline cirrhosis. Outcome measures at year 5
were summarized similarly using an on-treatment analysis,
whereby all patients on study with non-missing data were
analyzed. The Wilcoxon rank-sum test and Fisher’s exact
Chronic 
HBV 
paents 
(HBeAg–) 
and 
(HBeAg+) 
TDF 300 mg 
(n = 426) 
ADV 10 mg 
(n = 215) 
Open-label TDF 300 mg 
Study Year 0 1 5 8 
Biopsy 
mandatory mandatory oponal 
Randomized and treated Cirrhosis at baseline 
(n = 152)
No cirrhosis at baseline
(n = 482)
Completed double-blind phase
(Year 1) n = 147; 95.5% n = 461; 95.6%
Entered open-label phase n = 142; 92.2% n = 437; 90.7%
Completed Year 5 n = 123; 79.9% n = 362; 75.1%
Paired biopsies at baseline
and Year 5 n = 96; 62.3% n = 252; 52.3%
a
b
Fig. 1 Study design and patient
disposition. a The designs of the
two phase-3 randomized
double-blind placebo-controlled
studies have been described
previously [10–12]. Briefly, 641
patients with chronic HBV
infection were randomized to
tenofovir disoproxil fumarate
(TDF) 300 mg daily (n = 426)
or adefovir dipivoxil (ADV)
10 mg daily (n = 215) for
1 year. Afterward, patients were
eligible to receive TDF 300 mg
daily in an open-label extension
study for up to 9 additional
years. Mandatory liver biopsies
were obtained at baseline and
1 year. A third, optional biopsy
was obtained at year 5. b Of 641
patients randomized, 634 had
liver biopsy data available at
baseline. Of these 634, 152 were
classified as having cirrhosis
and 482 as having no cirrhosis.
HBeAg- hepatitis B e antigen
negative, HBsAg? hepatitis B
surface antigen positive, HBV
hepatitis B virus
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test were used to compare continuous and categorical
variables, respectively. Proportions of patients with HBsAg
loss were estimated using the Kaplan-Meier method;
comparison between groups was done via log rank test.
Histologic improvements (Ishak fibrosis stage and Knodell
necroinflammatory score) were compared using Fisher’s
exact test on on-treatment data.
Results
A total of 641 patients were randomized in the two phase-3
clinical trials (Fig. 1a). Of the original cohort, 91.3 % of
patients (n = 585) entered the open-label phase, and
76.3 % (n = 489) completed 5 years of treatment.
Baseline patient and disease characteristics
Baseline biopsies were obtained in 634 of 641 patients; of
these, 152 (24.0 %) had cirrhosis at baseline and 482
(76.0 %) did not (Fig. 1b). Of the patients with baseline
biopsies, 348 (54.9 %) also had biopsies at year 5 [10].
Biopsies were not performed in 141 patients at year 5,
primarily because patients refused the procedure. Baseline
characteristics of patients with and without cirrhosis are
described below and summarized in Table 1. Of the pa-
tients with baseline cirrhosis, none were Child-Pugh B or
C, none had a history of a decompensating event (e.g.,
hepatic encephalopathy, ascites), and none had two or more
of the following laboratory abnormalities: INR C1.7, total
bilirubin C2 mg/dl, or albumin B3.5 g/dl.
Table 1 Baseline demographic and disease characteristics
Factor Cirrhosis at baseline
(n = 152)
No cirrhosis at
baseline (n = 482)
p value
Patients [40 years of age [n (%)] 104 (68.4) 218 (45.2) \0.001
Male [n (%)] 123 (80.9) 345 (71.6) 0.026
Mean (SD) BMI (kg/m2) n = 151 26.5 (4.6) n = 479 25.1 (4.7) \0.001
Asian [n (%)] 39 (25.7) 148 (30.7) 0.262
Genotype [n (%)] 0.043
A 34 (22.4) 67 (13.9)
B 10 (6.6) 64 (13.3)
C 27 (17.8) 83 (17.2)
D 73 (48.0) 239 (49.6)
Othera 8 (5.3) 29 (6.0)
HBeAg positive [n (%)] 60 (39.5) 199 (41.3) 0.706
Previous lamivudine experience [12 weeks [n (%)] 20 (13.2) 55 (11.4) 0.566
Previous interferon experience [n (%)] 27 (17.8) 79 (16.4) 0.709
Mean (SD) HBV DNA (log10 IU/ml) 6.8 (1.43) 6.9 (1.51) 0.288
Mean (SD) HBsAg (log10 IU/ml) 3.9 (0.7) 4.1 (0.7) 0.017
Mean (SD) albumin (g/dl) 4.0 (0.4) 4.2 (0.3) \0.001
Mean (SD) platelet count (cells/ll) 178,200 (50,350) 218,600 (54,460) \0.001
Mean (SD) Knodell necroinflammatory score 9 (1.6) 8 (2.4) \0.001
Ishak fibrosis stage [n (%)] \0.001
0 0 1 (0.2)
1 0 20 (4.1)
2 0 248 (51.5)
3 0 153 (31.7)
4 0 60 (12.4)
5 29 (19.1) 0
6 123 (80.9) 0
Patients with normalb serum ALT levels [n (%)] 9 (5.9) 18 (3.7) 0.252
ALT alanine aminotransferase, BMI body mass index, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen, HBV hepatitis B virus, SD
standard deviation
a The ‘‘other’’ category includes patients with genotypes E, F, G, and H and patients with no genotype information available
b The upper limit of the normal range (ULN) for ALT was 34 IU/ml for females and 43 IU/ml for males
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Demographics
Statistically significant differences in age, sex, and body
mass index (BMI) were observed at baseline between pa-
tients with and without cirrhosis. Patients with cirrhosis
were more likely to be older than 40 years (68.4 vs.
45.2 %, p \ 0.001) and male (80.9 vs. 71.6 %, p = 0.026)
and to have a higher BMI (26.5 ± 4.6 vs. 25.1 ± 4.7 kg/
m2, p \ 0.001). Racial composition of both cohorts was
similar; 25.7 % of patients with cirrhosis and 30.7 % of
patients without cirrhosis were of Asian ancestry
(p = 0.262).
Virologic and serologic characteristics
At baseline, genotype D was the predominant HBV
genotype, detected in 48.0 % of patients with cirrhosis
and 49.6 % of patients without cirrhosis. The cohort with
cirrhosis had a higher proportion of patients with geno-
type A (22.4 vs. 13.9 %) and a lower proportion of pa-
tients with genotype B (6.6 vs. 13.3 %) than the cohort
without cirrhosis (p = 0.043 for distribution of genotypes
between cohorts). Mean levels of HBV DNA at baseline
were similar between the groups. Patients with cirrhosis
had lower mean quantitative HBsAg levels at baseline
than patients without cirrhosis. There was no statistical
difference in the percentage of patients with positive
HBeAg status at baseline between cohorts with and
without baseline cirrhosis (39.5 vs. 41.3 %, p = 0.706).
Clinical characteristics
Similar proportions of patients in both cohorts had normal
serum ALT levels at baseline. Patients with baseline cir-
rhosis were more likely to have lower levels of serum
albumin (p \ 0.001) and lower platelet counts
(p \ 0.001) than patients who had no cirrhosis at base-
line. Per protocol, all patients had compensated liver
function at baseline.
On-treatment factors
On-treatment factors for both patient groups are described
below and summarized in Table 2.
Virologic and serologic characteristics
After 5 years on study, nearly all patients in both cohorts
achieved and maintained a virologic response, regardless of
baseline cirrhosis status. At year 5, 99.2 % of the cohort
with cirrhosis and 98.0 % of the cohort without cirrhosis
had HBV DNA \69 IU/ml (p = 0.686); 99.2 % of the
cohort with cirrhosis and 97.4 % of the cohort without
cirrhosis had HBV DNA \29 IU/ml (p = 0.465). No pa-
tient in either cohort had persistent viremia, defined as
never having had undetectable HBV DNA. Moreover,
during year 5, only 4 of 495 patients experienced virologic
breakthrough, 3 of whom had documented non-adherence
to TDF.
Of the patients who were HBeAg positive at baseline,
61.9 and 45.4 % of patients with and without baseline
cirrhosis, respectively, experienced HBeAg loss (p =
0.075) by year 5. Both cohorts demonstrated an early de-
cline in circulating HBsAg; however, despite having a
higher mean baseline HBsAg level, the mean change in
HBsAg level at week 12 in the cohort without cirrhosis was
greater than in the cohort with cirrhosis (p = 0.037). By
year 5, HBsAg loss in the HBeAg-positive cohort occurred
in 14.4 and 8.3 % of patients with and without cirrhosis,
respectively (p = 0.188; on-treatment analysis; Kaplan-
Meier estimate). Only one HBeAg-negative patient had
HBsAg loss.
Clinical characteristics
The majority of patients achieved a biochemical response;
79.7 and 81.9 % of patients with and without baseline
cirrhosis, respectively, had normal ALT levels (p = 0.586)
at year 5. Greater increases in platelets (30,700 vs. 20,100
cells/ll; p = 0.030) and serum albumin (0.3 vs. 0.1 g/dl;
p \ 0.001) occurred in the cohort with cirrhosis, but both
cohorts experienced significant improvements in these two
parameters by year 5 on study. There were no episodes of
liver decompensation, such as ascites or variceal bleeding,
or liver failure observed in the two studies. Few patients in
either cohort developed HCC at 5 years [cirrhotics: 4.0 %
(n = 6) vs. noncirrhotics: 1.2 % (n = 6); p = 0.044]. At
the time of this analysis, of the 12 patients who had been
diagnosed with HCC, 3 died as a result of their disease, 4
with early-stage HCC achieved disease resolution via sur-
gery or radiofrequency ablation, and 5 continued to have
unresolved HCC [10].
Histologic characteristics
The 5-year liver biopsy was obtained in 96 (63.2 %) of 152
patients with baseline cirrhosis and 252 (52.3 %) of 482
patients without cirrhosis. Among these, 93.8 % of patients
with cirrhosis achieved an improvement in the Knodell
necroinflammatory score of C1 unit compared with 90.5 %
of patients without cirrhosis (p = 0.746) (Fig. 2). Only two
(0.8 %) patients, both initially without cirrhosis, experi-
enced a worsening of the Knodell necroinflammatory
score. All other patients had no change in the necroin-
flammatory score.
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Safety
A summary of adverse events reported in patients with and
without baseline cirrhosis through year 5 is provided in
Table 3. There were no statistically significant differences
between the two cohorts in key safety parameters. The
incidences of renal adverse events in the cohort with and
without baseline cirrhosis, as determined by an increase in
serum creatinine [0.5 mg/dl above baseline (1.4 vs.
0.7 %), phosphorus levels \2.0 mg/dl (1.4 vs. 0.9 %), and
creatinine clearance \50 ml/min (0.7 vs. 0.0 %), were all
low. The single patient with baseline cirrhosis who expe-
rienced on-study creatinine clearance \50 ml/min had
long-standing, medically managed hypertension, was
Table 2 Clinical outcomes at 5 years, by baseline cirrhosis status (on-treatment analysis)
Factor Cirrhosis at baseline
(n = 152)
No cirrhosis at
baseline (n = 482)
p value
HBV DNA \69 IU/ml [n/N (%)] 119/120 (99.2) 339/346 (98.0) 0.686
HBV DNA \29 IU/ml [n/N (%)] 119/120 (99.2) 337/346 (97.4) 0.465
Normal ALT level [n/N (%)] 94/118 (79.7) 286/349 (81.9) 0.586
Normalized ALT level [n/N (%)] 85/109 (78.0) 271/333 (81.4) 0.486
HBsAg lossa,b (%) 14.4 8.3 0.188
Mean (SD) change in HBsAg from baseline
to week 12 (log10 IU/ml)
n = 149
-0.1 (0.5)
n = 470
-0.2 (0.4)
0.037
HBeAg lossa [n/N (%)] 26/42 (61.9) 54/119 (45.4) 0.075
Mean (SD) change in platelets (cells/ll) n = 117
30,700 (43,930)
n = 343
20,100 (40,150)
0.030
Mean (SD) change in albumin (g/dl) n = 119
0.3 (0.4)
n = 353
0.1 (0.3)
\0.001
Development of HCC [n/N (%)] 6/152 (4.0) 6/482 (1.2) 0.044
No patients in either group developed hepatic encephalopathy or variceal bleeding; one patient without cirrhosis at baseline developed ascites (in
association with HCC)
ALT alanine aminotransferase, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen, HBV hepatitis B virus, HCC hepatocellular
carcinoma, SD standard deviation
a HBeAg-positive patients only
b Kaplan-Meier estimated proportion
p = 0.746a
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Fig. 2 Histologic changes at year 5 among patients with and without
baseline cirrhosis. Among 348 patients with paired biopsies at year 5
of treatment, 96 had baseline cirrhosis and 252 had no baseline
cirrhosis. ap value calculated using Fisher’s exact test. Necroinflam-
matory response (Knodell scores) at year 5. Ninety-four percent of
patients in the cohort with baseline cirrhosis and 91 % in the cohort
with no baseline cirrhosis experienced improvement in the Knodell
necroinflammatory score. Improvement was defined as a decrease in
score of C1 unit; worsening was defined as an increase in score of C1
unit
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[50 years of age, and was prescribed nonsteroidal antiin-
flammatory medications as needed.
Discussion
Historically, CHB patients with cirrhosis have poorer
prognosis, including greater risk for the development of
HCC, than their CHB counterparts without cirrhosis [14,
15]. Our analyses suggest that, for the most part, long-term
TDF treatment in CHB patients can lead to similar out-
comes in patients with or without baseline cirrhosis. The
exception is for HCC development, where our analyses
revealed a significantly higher rate of HCC development in
patients with baseline cirrhosis than without (4.0 vs. 1.2 %,
p = 0.044). Nevertheless, the overall incidence of HCC
development in either cohort was low. Rates of virologic
response observed in our current analyses were similar
between cohorts, suggesting that at year 5 in our studies, at
least, the presence of cirrhosis at baseline may contribute
more to the development of HCC during the study time-
frame than viral load on therapy does. Therefore, surveil-
lance for HCC should be performed regardless of HBV
DNA suppression.
It has been demonstrated that decompensated cirrhosis is
associated with poorer outcomes [16]. Moreover, HBV
DNA suppression has been shown to prevent progression
of clinical disease [8]. Because the two clinical studies
excluded patients with decompensated liver disease, our
analyses cannot address the effect of TDF on the clinical
course of decompensated patients. However, over 5 years,
there were no cases of hepatic decompensation in either
study, an encouraging observation given the 2.7 % annual
rate of liver decompensation previously observed in CHB
patients [17].
In our analyses, patients without cirrhosis were more
likely to experience early HBsAg declines of greater
magnitude. This observation might be related to the sig-
nificantly higher level of HBsAg that noncirrhotic patients
had at baseline, a pattern that has been reported before [18].
A detailed report on the kinetics of HBsAg decline and loss
in studies 102 and 103 was recently published, confirming
a significant correlation between early decline and loss of
HBsAg [19].
The generalizability of our findings to patients with
cirrhosis may be limited to those with compensated disease
given the patient population enrolled under the studies. In
addition, the analyses reported were retrospective and
therefore subject to the limitations inherent to retrospective
analyses.
Through 5 years of treatment, no significant differences
were observed between the two cohorts in the incidence of
treatment-emergent adverse events. Importantly, the oc-
currence of renal adverse events was low in both cohorts.
In summary, our analyses provide evidence that treatment
with TDF up to 5 years is equally efficacious and safe in
patients with CHB, regardless of whether patients with
CHB are noncirrhotic or have well-compensated cirrhosis
at baseline.
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